<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02421458</url>
  </required_header>
  <id_info>
    <org_study_id>M15CRH</org_study_id>
    <nct_id>NCT02421458</nct_id>
  </id_info>
  <brief_title>Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer</brief_title>
  <acronym>COOPERATION</acronym>
  <official_title>Dutch Randomized Multicenter Trial COmparing twO PalliativE RAdiaTION Schemes for Incurable Head and Neck Cancer (COOPERATION)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RCT to compare two radiation schemes for palliative HeadNeck cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A substantial proportion of patients with head and neck (HNC) are not suitable for curative
      treatment with surgery and/or (chemo)radiotherapy (CRT) because of very advanced stage,
      significant comorbidities, bad general condition, distant metastasis, or a combination of
      these factors. Although radiotherapy (RT) is a commonly used option to achieve durable
      disease control and to alleviate troublesome symptoms, the data about the optimal radiation
      scheme and the impact of these schedules on quality of life (QoL) of these vulnerable
      patients is extremely scarce.

      Although different radiation schemes are used worldwide (in the Netherlands, at least 15
      different radiation schedules are used), it is currently not possible to identify the best RT
      scheme, based only on retrospective studies because of the major differences between these
      studies with regard to patient's demographics, radiation schedules given, the radiation
      technique used etc. Furthermore, no any information is available on the impact of these
      schemes on treatment-related toxicity and QoL.

      This illustrates the urgent need for a multicenter randomized controlled trial (RCT) to
      identify the most optimal schemes of RT for this group of patients. Therefore, the
      investigators intend to initiate a prospective RCT comparing the survival, loco-regional
      control, toxicity, and QoL of two commonly used schemes. This study will be the first of his
      kind for palliative patients with HNC and will compare a short-course (6 fractions) with a
      long-course of radiotherapy (16 fractions). Because most of patients with incurable HNC have
      a poor performance status and major comorbidity and prefer limited number of visits to the
      hospital, it is quite reasonable to investigate whether a short scheme of radiotherapy with
      limited number of visits to the clinic as good as a relatively long-course of radiotherapy in
      terms of outcome, toxicity and QoL. This delicate balance between outcomes, possible toxicity
      and patient's comfort would justify the initiation of such randomized trial. The results of
      this study will in the nearby future enable us to indicate the radiation scheme best suits
      which patient category
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>time to loco-regional progression</measure>
    <time_frame>4 months</time_frame>
    <description>caculated from date of response until the date of clinical deteriotion; accoriding to RECIST</description>
  </primary_outcome>
  <primary_outcome>
    <measure>impact of both radiation schemes on QoL</measure>
    <time_frame>2 years</time_frame>
    <description>this will be measured by the EORTC questionnaires C30 and HN35; analysis will be performed by a random effects regression model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival rates</measure>
    <time_frame>4 months</time_frame>
    <description>RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>loco-regional control rates</measure>
    <time_frame>3 months</time_frame>
    <description>caculated from date of response until the date of clinical deteriotion; according to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall response rates</measure>
    <time_frame>2 year</time_frame>
    <description>caculated from date of response until the date of clinical deteriotion; accoriding to RECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance to the study treatments as assessed by completed treatment and follow-up visits</measure>
    <time_frame>4 months</time_frame>
    <description>number of treatment fractions and follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the incidence of grade ≥ 2 acute and late toxicity</measure>
    <time_frame>2 years</time_frame>
    <description>scoring of AE according tot CTC 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Head and Neck Neoplasms</condition>
  <arm_group>
    <arm_group_label>arm 1: 6 fractions of radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiation in a 6 fractions scheme and a daily dose of 6 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>arm 2: 16 fractrions of radiation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>radiation in a 16 fractions scheme and a daily dose of 3.125 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>6 x 6 Gy</intervention_name>
    <description>radiation in 6 fraction of 6 Gy, twice a week during 3 weeks</description>
    <arm_group_label>arm 1: 6 fractions of radiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>16 x 3.125 Gy</intervention_name>
    <description>radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks</description>
    <arm_group_label>arm 2: 16 fractrions of radiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        • Newly diagnosed patients with primary non-metastatic carcinoma located in the oral
        cavity, oropharynx, larynx (except T1 glottic), hypopharynx, nasopharynx, paranasal sinuses
        and salivary gland and carcinoma of unknown primary in the head and neck region who are not
        suitable for radical treatment with surgery or (chemo) and, therefore, planned for
        treatment with radiotherapy in palliative setting.

        OR

          -  Newly diagnosed patients with primary head and neck carcinoma with limited metastatic
             disease in a good general condition and few comorbidities (ACE-25 &lt;3) with life
             expectancy of at least 6 months are also eligible.

          -  No chemotherapy or surgery is allowed before inclusion.

          -  Age ≥ 18 years

          -  WHO performance status 0-2

          -  Signed written informed consent

        Exclusion Criteria:

          -  Patients with previously radiation treatment in the head and neck region, for any
             reason.

             * Chemotherapy or surgery for head and neck tumor before inclusion and no other
             concomitant anti-cancer therapy is allowed during study treatment.

          -  Patients with head and neck malignancies arising from skin, nose, thyroid gland or
             esophagus.

          -  Patients with advanced stage sarcoma or lymphoma of the head and neck region.

          -  Expected life expectancy of less than 3 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abrahim Al-Mamgani, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Netherlands Cancer Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Abrahim Al-Mamgani, MD, PhD</last_name>
    <phone>+ 31 20 512 9111</phone>
    <email>a.almamgani@nki.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <state>Overijssel</state>
        <zip>7513 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>F Ong, MD, PhD</last_name>
      <phone>+3153 487 2000</phone>
      <email>f.ong@mst.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <state>Zuid Holland</state>
        <zip>2333 ZA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin A de Jong, MD</last_name>
      <phone>+31 71 526 9111</phone>
      <email>M.A.de_Jong@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Corine MH de Jong</last_name>
      <email>C.M.H.de_Jong@lumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Derek Rietveld, MD, PhD</last_name>
      <phone>020 4444444</phone>
      <email>dhf.rietveld@vumc.nl</email>
    </contact>
    <investigator>
      <last_name>Derek Rietveld, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <zip>19066CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abrahim Al-Mamgani, MD,PhD</last_name>
      <phone>+31 20 512 9111</phone>
      <email>a.almamgani@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Hester Visser</last_name>
      <phone>+31 20 512 9111</phone>
      <email>he.visser@nki.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Radiotherapiegroep, lokatie Arnhem</name>
      <address>
        <city>Arnhem</city>
        <zip>6815AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bas Kreike, MD</last_name>
      <phone>+31 26-3712412</phone>
      <email>b.kreike@arnhemrti.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haaglanden Medisch Centrum</name>
      <address>
        <city>Den Haag</city>
        <zip>2260 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J Franssen, MD</last_name>
      <phone>(070) 330 20 00</phone>
      <email>j.franssen@haaglandenmc.nl</email>
    </contact>
    <investigator>
      <last_name>J Franssen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans Langendijk, MD PhD</last_name>
      <phone>+3150 361 6161</phone>
      <email>j.a.langendijk@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>Hans Langendijk, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastro Clinic</name>
      <address>
        <city>Maastricht</city>
        <zip>NL-6229 ET</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank Hoebers, MD</last_name>
      <phone>+31 88 4455521</phone>
      <email>frank.hoebers@maastro.nl</email>
    </contact>
    <investigator>
      <last_name>Frank Hoebers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud umc</name>
      <address>
        <city>NIjmegen</city>
        <zip>6225GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lia G. Verhoef, MD, PhD</last_name>
      <phone>+31 24 361 1111</phone>
      <email>Lia.Verhoef@radboudumc.nl</email>
    </contact>
    <investigator>
      <last_name>Lia Verhoef, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <zip>3008EA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Tans, MD, PhD</last_name>
      <email>l.tans@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Lisa Tans, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituut Verbeeten</name>
      <address>
        <city>Tilburg</city>
        <zip>5042 SB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>R. L Poorter, MD</last_name>
      <phone>+31 13 594 7559</phone>
      <email>poorter.r@bvi.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2015</study_first_submitted>
  <study_first_submitted_qc>April 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2015</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

